Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS

PURPOSE: Since the KRAS mutation is not responsible for all metastatic colorectal cancer (mCRC) patients with resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MoAb) therapy, new predictive and prognostic factors are actively being sought. METHODS: We retrospectively ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Kishiki, Tomokazu, Ohnishi, Hiroaki, Masaki, Tadahiko, Ohtsuka, Kouki, Ohkura, Yasuo, Furuse, Jyunji, Watanabe, Takashi, Sugiyama, Masanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965831/
https://www.ncbi.nlm.nih.gov/pubmed/24500024
http://dx.doi.org/10.1007/s00280-014-2401-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965831/
https://www.ncbi.nlm.nih.gov/pubmed/24500024
http://dx.doi.org/10.1007/s00280-014-2401-4

Ejemplares similares